KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Long-Term Debt Repayments (2018 - 2025)

NovoCure (NVCR) has disclosed Long-Term Debt Repayments for 8 consecutive years, with $560.9 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $560.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $560.9 million through Dec 2025, up 4244.03% year-over-year, with the annual reading at $560.9 million for FY2025, 4244.03% up from the prior year.
  • Long-Term Debt Repayments hit $560.9 million in Q4 2025 for NovoCure, up from $12.9 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $560.9 million in Q4 2025 to a low of $3000.0 in Q2 2023.
  • Historically, Long-Term Debt Repayments has averaged $47.8 million across 5 years, with a median of $7000.0 in 2021.
  • Biggest five-year swings in Long-Term Debt Repayments: plummeted 100.0% in 2021 and later skyrocketed 430333.33% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $7000.0 in 2021, then changed by 0.0% to $7000.0 in 2022, then tumbled by 57.14% to $3000.0 in 2023, then surged by 430333.33% to $12.9 million in 2024, then soared by 4244.03% to $560.9 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for NVCR at $560.9 million in Q4 2025, $12.9 million in Q2 2024, and $3000.0 in Q2 2023.